Boan Biotech is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $4.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Boan Biotech's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Trulicity BA5101 |
Eli Lilly | Biosimilar | 2027 | US trial cleared by FDA, Aug 2024 | $4.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Boan Biotech's share of it.